GILD - Gilead Sciences, Inc.
IEX Last Trade
78.98
-0.470 -0.595%
Share volume: 6,204,270
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$79.45
-0.47
-0.59%
Fundamental analysis
42%
Profitability
48%
Dept financing
24%
Liquidity
19%
Performance
47%
Performance
5 Days
2.97%
1 Month
1.22%
3 Months
24.80%
6 Months
12.26%
1 Year
9.12%
2 Year
42.29%
Key data
Stock price
$78.98
DAY RANGE
$78.60 - N/A
52 WEEK RANGE
$61.32 - $85.05
52 WEEK CHANGE
$0.11
DIVIDEND
$0.77
EX-DIVIDEND DATE
06/14/2024
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Daniel O'Day
Region: US
Website: https://www.gilead.com/
Employees: 17,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: https://www.gilead.com/
Employees: 17,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Recent news